Pilot study of estramustine added to radiosurgery and radiotherapy for treatment of high grade glioma

Howard Landy, Arnold Markoe, Priscilla Potter, Garrett Lasalle, Angela Marini, Niramol Savaraj, Isildinha Reis, Deborah O Heros, Medhi Wangpaichitr, Lynn G Feun

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Patients with high grade glioma generally have poor prognoses. Addition of radiosensitizing agents might improve the response to irradiation. The chemotherapeutic agent estramustine sensitizes experimental gliomas to radiation. Gliomas express estramustine binding proteins, and cytotoxic concentrations of estramustine metabolites are found in gliomas after oral administration. Twenty three patients, aged 25-78, with new or recurrent high grade glioma were treated with estramustine and radiosurgery and/or radiotherapy. Patients with recurrent tumors were treated with estramustine and Gamma Knife stereotactic radiosurgery; eligible tumors were limited to 4 cm maximal diameter. Patients with newly diagnosed tumors were treated with estramustine and fractionated radiotherapy, with radiosurgery also performed if the tumor was less than 4 cm maximal diameter. Estramustine (16 mg/kg per day orally) was started three days prior to radiosurgery, or, if only radiotherapy was performed, on the first day of radiotherapy. Estramustine was continued until the completion of radiosurgery and/or radiotherapy (72 Gy, 60 fractions, 1.2 Gy bid over 6 weeks). Of the 13 patients treated for newly diagnosed glioblastoma, median survival was 16 months with 38% 2-year survival. Of five patients treated for recurrent glioblastoma, survival was 3, 8, 9, 15, and 23+ months. Two patients with recurrent anaplastic astrocytoma survived for 24 and 48+ months. One patient with recurrent anaplastic mixed glioma survived 5+ months. Two patients with newly diagnosed anaplastic oligodendroglioma survived 20 and 42+ months. Four of the new glioblastoma patients developed deep vein thrombosis. The results of this pilot study indicate some benefit, and further investigation incorporating estramustine into clinical trials is suggested.

Original languageEnglish
Pages (from-to)215-220
Number of pages6
JournalJournal of Neuro-Oncology
Volume67
Issue number1-2
DOIs
StatePublished - Mar 1 2004

Fingerprint

Estramustine
Radiosurgery
Glioma
Radiotherapy
Glioblastoma
Therapeutics
Survival
Neoplasms
Radiation-Sensitizing Agents
Oligodendroglioma
Astrocytoma
Venous Thrombosis
Oral Administration

Keywords

  • Brain tumor
  • Estramustine
  • Glioma
  • Radiosurgery
  • Radiotherapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neuroscience(all)

Cite this

Pilot study of estramustine added to radiosurgery and radiotherapy for treatment of high grade glioma. / Landy, Howard; Markoe, Arnold; Potter, Priscilla; Lasalle, Garrett; Marini, Angela; Savaraj, Niramol; Reis, Isildinha; Heros, Deborah O; Wangpaichitr, Medhi; Feun, Lynn G.

In: Journal of Neuro-Oncology, Vol. 67, No. 1-2, 01.03.2004, p. 215-220.

Research output: Contribution to journalArticle

@article{b5b1977ef2e0496bab4e52286187f407,
title = "Pilot study of estramustine added to radiosurgery and radiotherapy for treatment of high grade glioma",
abstract = "Patients with high grade glioma generally have poor prognoses. Addition of radiosensitizing agents might improve the response to irradiation. The chemotherapeutic agent estramustine sensitizes experimental gliomas to radiation. Gliomas express estramustine binding proteins, and cytotoxic concentrations of estramustine metabolites are found in gliomas after oral administration. Twenty three patients, aged 25-78, with new or recurrent high grade glioma were treated with estramustine and radiosurgery and/or radiotherapy. Patients with recurrent tumors were treated with estramustine and Gamma Knife stereotactic radiosurgery; eligible tumors were limited to 4 cm maximal diameter. Patients with newly diagnosed tumors were treated with estramustine and fractionated radiotherapy, with radiosurgery also performed if the tumor was less than 4 cm maximal diameter. Estramustine (16 mg/kg per day orally) was started three days prior to radiosurgery, or, if only radiotherapy was performed, on the first day of radiotherapy. Estramustine was continued until the completion of radiosurgery and/or radiotherapy (72 Gy, 60 fractions, 1.2 Gy bid over 6 weeks). Of the 13 patients treated for newly diagnosed glioblastoma, median survival was 16 months with 38{\%} 2-year survival. Of five patients treated for recurrent glioblastoma, survival was 3, 8, 9, 15, and 23+ months. Two patients with recurrent anaplastic astrocytoma survived for 24 and 48+ months. One patient with recurrent anaplastic mixed glioma survived 5+ months. Two patients with newly diagnosed anaplastic oligodendroglioma survived 20 and 42+ months. Four of the new glioblastoma patients developed deep vein thrombosis. The results of this pilot study indicate some benefit, and further investigation incorporating estramustine into clinical trials is suggested.",
keywords = "Brain tumor, Estramustine, Glioma, Radiosurgery, Radiotherapy",
author = "Howard Landy and Arnold Markoe and Priscilla Potter and Garrett Lasalle and Angela Marini and Niramol Savaraj and Isildinha Reis and Heros, {Deborah O} and Medhi Wangpaichitr and Feun, {Lynn G}",
year = "2004",
month = "3",
day = "1",
doi = "10.1023/B:NEON.0000021825.41221.b5",
language = "English",
volume = "67",
pages = "215--220",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "1-2",

}

TY - JOUR

T1 - Pilot study of estramustine added to radiosurgery and radiotherapy for treatment of high grade glioma

AU - Landy, Howard

AU - Markoe, Arnold

AU - Potter, Priscilla

AU - Lasalle, Garrett

AU - Marini, Angela

AU - Savaraj, Niramol

AU - Reis, Isildinha

AU - Heros, Deborah O

AU - Wangpaichitr, Medhi

AU - Feun, Lynn G

PY - 2004/3/1

Y1 - 2004/3/1

N2 - Patients with high grade glioma generally have poor prognoses. Addition of radiosensitizing agents might improve the response to irradiation. The chemotherapeutic agent estramustine sensitizes experimental gliomas to radiation. Gliomas express estramustine binding proteins, and cytotoxic concentrations of estramustine metabolites are found in gliomas after oral administration. Twenty three patients, aged 25-78, with new or recurrent high grade glioma were treated with estramustine and radiosurgery and/or radiotherapy. Patients with recurrent tumors were treated with estramustine and Gamma Knife stereotactic radiosurgery; eligible tumors were limited to 4 cm maximal diameter. Patients with newly diagnosed tumors were treated with estramustine and fractionated radiotherapy, with radiosurgery also performed if the tumor was less than 4 cm maximal diameter. Estramustine (16 mg/kg per day orally) was started three days prior to radiosurgery, or, if only radiotherapy was performed, on the first day of radiotherapy. Estramustine was continued until the completion of radiosurgery and/or radiotherapy (72 Gy, 60 fractions, 1.2 Gy bid over 6 weeks). Of the 13 patients treated for newly diagnosed glioblastoma, median survival was 16 months with 38% 2-year survival. Of five patients treated for recurrent glioblastoma, survival was 3, 8, 9, 15, and 23+ months. Two patients with recurrent anaplastic astrocytoma survived for 24 and 48+ months. One patient with recurrent anaplastic mixed glioma survived 5+ months. Two patients with newly diagnosed anaplastic oligodendroglioma survived 20 and 42+ months. Four of the new glioblastoma patients developed deep vein thrombosis. The results of this pilot study indicate some benefit, and further investigation incorporating estramustine into clinical trials is suggested.

AB - Patients with high grade glioma generally have poor prognoses. Addition of radiosensitizing agents might improve the response to irradiation. The chemotherapeutic agent estramustine sensitizes experimental gliomas to radiation. Gliomas express estramustine binding proteins, and cytotoxic concentrations of estramustine metabolites are found in gliomas after oral administration. Twenty three patients, aged 25-78, with new or recurrent high grade glioma were treated with estramustine and radiosurgery and/or radiotherapy. Patients with recurrent tumors were treated with estramustine and Gamma Knife stereotactic radiosurgery; eligible tumors were limited to 4 cm maximal diameter. Patients with newly diagnosed tumors were treated with estramustine and fractionated radiotherapy, with radiosurgery also performed if the tumor was less than 4 cm maximal diameter. Estramustine (16 mg/kg per day orally) was started three days prior to radiosurgery, or, if only radiotherapy was performed, on the first day of radiotherapy. Estramustine was continued until the completion of radiosurgery and/or radiotherapy (72 Gy, 60 fractions, 1.2 Gy bid over 6 weeks). Of the 13 patients treated for newly diagnosed glioblastoma, median survival was 16 months with 38% 2-year survival. Of five patients treated for recurrent glioblastoma, survival was 3, 8, 9, 15, and 23+ months. Two patients with recurrent anaplastic astrocytoma survived for 24 and 48+ months. One patient with recurrent anaplastic mixed glioma survived 5+ months. Two patients with newly diagnosed anaplastic oligodendroglioma survived 20 and 42+ months. Four of the new glioblastoma patients developed deep vein thrombosis. The results of this pilot study indicate some benefit, and further investigation incorporating estramustine into clinical trials is suggested.

KW - Brain tumor

KW - Estramustine

KW - Glioma

KW - Radiosurgery

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=12144287560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12144287560&partnerID=8YFLogxK

U2 - 10.1023/B:NEON.0000021825.41221.b5

DO - 10.1023/B:NEON.0000021825.41221.b5

M3 - Article

C2 - 15072470

AN - SCOPUS:12144287560

VL - 67

SP - 215

EP - 220

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 1-2

ER -